Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
ClosedOpportunity RFA-OH-21-007

Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24)

Centers for Disease Control and Prevention - ERA · Department of Health and Human Services

At a glance

Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24) is a closed federal cooperative agreement opportunity from the Centers for Disease Control and Prevention - ERA (Department of Health and Human Services). The application deadline was March 25, 2021. Individual awards are listed as $800K – $1.1M, with about 1 award expected and $5.5M in total estimated funding. Applicant types listed as eligible include others (see notice). Cost sharing is not required. It is funded under Assistance Listing 93.262 (Occupational Safety and Health Program).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Posted
Jan 22, 2021
Close date
Mar 25, 2021
Award floor
$800,000
Award ceiling
$1,100,000
Est. total funding
$5,500,000
Expected awards
1
Cost sharing
Not required
Funding instrument
Cooperative Agreement
Opportunity category
Discretionary

Who can apply

  • Others (see notice)

Additional information on eligibility (from the notice)

This is a single-eligibility award. Only the University of Pittsburgh, the institution with the existing National Mesothelioma Virtual Bank for Translational Research, is eligible to apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The National Mesothelioma Virtual Bank for Translational Research (NMVB) was established in fiscal year 2006 to serve as an exceptional resource for mesothelioma research. RFA-OH-21-007 will continue the NMVB to advance biomedical research for malignant mesothelioma to gain a better understanding of the disease and its progression, and the potential development of new treatments, therapeutics, and diagnostics for mesothelioma. Continued support to the NMVB will allow expansion of collection of biospecimens, related data, and other information. NIOSH intends to continue the NMVB at the University of Pittsburgh to accomplish the following important program priorities: maintain uninterrupted assistance to mesothelioma researchers; avoid critical support gaps for current or pending mesothelioma research efforts; demonstrate a sustained public health commitment to advancing the treatment of mesothelioma; and affirm a sustained commitment to workers and other people impacted by this disease.

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.262

Historical data · not a prediction
FY24$131M
FY25$128M
FY26$113M est.
Source: SAM.gov Assistance Listing 93.262. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Centers for Disease Control and Prevention - ERA
beg8@cdc.gov
404-498-2015

Quick answers

Who is eligible to apply for this opportunity?

The official notice lists these applicant types as eligible: Others (see notice). Additional restrictions may apply; review the full notice.

How much funding is available through this opportunity?

Per the notice, individual awards are listed as $800k – $1.1m, total estimated program funding is $5,500,000 and the agency expects to make about 1 awards.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-OH-21-007), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.